Abbott (ABT): Can Libre Keep Growing as Glucose Monitoring Becomes More Competitive?

Abbott Laboratories (NYSE:ABT) benefits each time a patient replaces a glucose sensor. Continuous glucose monitoring, or CGM, sales grew 9.5% excluding currency effects in the second quarter of 2026, versus 7.6% in the first quarter. The investment question is whether repeated purchases can sustain profitable growth as competitors improve their products and insurers influence patient […]